Martinsried, Germany

Adam Grabarek

This inventor holds 1 USPTO granted patent. Top assignee: Coriolis Pharma Research Gmbh. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adam Grabarek. Retrieved from https://idiyas.com/inventor/adam-grabarek

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Adam Grabarek and Machine-Learning-Based Cell Detection

Introduction

Adam Grabarek is an inventor associated with Martinsried, Germany, and Coriolis Pharma Research GmbH. His patent work addresses the analysis of cell-based products using flow-imaging microscopy and machine learning.

Latest Patents

Grabarek is associated with 1 patent, titled “FIM-CNN for Detection of Viable Cells and/or Particulate Impurities.” The disclosed method uses a convolutional neural network trained on classified flow-imaging microscopy images to quantify viable cells and distinguish them from different types of particulate impurities in a cell-based product sample.

Career Highlights

Grabarek’s listed invention applies image classification to a practical challenge in cell-product analysis. By training a CNN on examples of viable cells and impurities, the method aims to support their identification and quantification.

Collaborations

His listed coworkers include Alexandra Roesch and Andrea Hawe. The patent is associated with Coriolis Pharma Research GmbH.

Conclusion

Adam Grabarek’s patent work combines flow-imaging microscopy and convolutional neural networks to help detect viable cells and particulate impurities in cell-based products.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…